FIGURE

Fig. 9

ID

ZDB-FIG-240910-22

Publication

Gu et al., 2024 - Therapeutic liposomal combination to enhance chemotherapy response and immune activation of tumor microenvironment

Other Figures

All Figure Page

Back to All Figure Page

Fig. 9

Anti-tumor immunity evaluation in CT26-tumor bearing mice. A. The percentage of DCs, matured DC, inflammatory monocytes and immature myeloid cells in the TME after treatments. B. The percentage of macrophages, M1 macrophages, M2 macrophages and M1/M2 ratio in the TME after treatments. C. The percentage of DCs, matured DC, inflammatory monocytes and immature myeloid cells in the spleen after treatments. D. The percentage of macrophages, M1 macrophages, M2 macrophages and M1/M2 ratio in the spleen after treatments. E. The percentage of leukocytes, CD3+ T cells and CD4+ T cells in the TME after treatments. F. The percentage of CD8+ T cells, IL-2+CD8+ T cells, IFN-γ+CD8+ T cells and TNF-α+CD8+ T cells in the TME after treatments. G. The percentage of leukocytes, CD3+ T cells and CD4+ T cells in the spleen after treatments. F. The percentage of CD8+ T cells, IL-2+CD8+ T cells, IFN-γ+CD8+ T cells and TNF-α+CD8+ T cells in the spleen after treatments. (n = 4, results were shown in mean ± S.D., *, p < 0.05, **, p < 0.01, p < 0.01, ***, p < 0.001, ****, p < 0.0001).

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ J. Control Release